Taysha Gene Therapies Strategy and Business Model

Executive Overview

Taysha Gene Therapies is a clinical-stage biotechnology company focused on adeno-associated virus (AAV) gene therapies for severe monogenic diseases of the central nervous system (CNS). Founded in 2020 around technology licensed from The University of Texas Southwestern Medical Center and headquartered in Dallas, Texas, Taysha has evolved from a broad CNS gene-therapy platform into a more focused rare-neurology developer centered on Rett syndrome. Its lead value driver has been TSHA-102, an investigational gene therapy designed to address the underlying MECP2 deficiency in Rett syndrome while managing the gene-dosage problem that has historically made this biology difficult. That focus is strategically important: in small-cap biotech, the difference between a broad pipeline story and a fundable company often comes down to concentrating capital behind the best risk-adjusted program.

Taysha operates in the high-risk, high-upside part of biotech where value is created through clinical data, regulatory progress, manufacturing readiness, and partnerships rather than current product sales. Its operational footprint is still development-led rather than commercial, with U.S.-based corporate operations and a network of clinical, manufacturing, and testing partners. As of FY2024, Taysha remained pre-commercial, so revenue was limited and non-product in nature.

Taysha at a Glance

Logo
Common name	Taysha
Full legal name	Taysha Gene Therapies, Inc.
Headquarters	Dallas, Texas, United States
Ownership	Public company; Nasdaq-listed
Ticker	TSHA
Exchange	NASDAQ
Market Cap	$1.98B
Revenue (FY2024)	#N/A
Founding / major historical milestones	Founded in 2020; completed its initial public offering in 2020; later narrowed its portfolio to focus capital on highest-priority CNS gene-therapy programs; announced a strategic transaction with Astellas in 2023; continued clinical advancement of TSHA-102 in 2024.
Industry or industries	Biotechnology; gene therapy; rare-disease therapeutics; CNS disorders
Key products or services	Investigational AAV-based gene therapies led by TSHA-102 for Rett syndrome; rare CNS gene-therapy pipeline assets; licensing and partnering rights around platform and product candidates
Geographic footprint	U.S.-based corporate footprint with clinical, manufacturing, and research activities supported through partners in North America and other markets as required by development programs
Business segments as officially reported	One operating and reportable segment
Company website	https://www.tayshagtx.com/

1. What Is the Strategy of Taysha?

Taysha’s public strategy is best understood as a focused rare-disease gene-therapy model rather than a broad platform roll-up. Recent company communications have emphasized concentrating resources on the most differentiated and value-relevant programs, especially TSHA-102 in Rett syndrome, while using partnerships and disciplined spending to extend runway and improve the probability of clinical and regulatory success.

1a. What is the winning aspiration of Taysha?

Taysha’s winning aspiration is to develop disease-modifying or potentially transformative gene therapies for severe monogenic CNS disorders, beginning with Rett syndrome and other conditions where gene replacement could address the root cause of disease. In practical terms, “winning” for Taysha does not currently mean maximizing near-term revenue; it means generating convincing clinical data, establishing a viable regulatory path, and turning TSHA-102 into an approvable and commercially relevant therapy. Publicly, management has framed the company around milestone creation rather than broad financial targets, which is typical for a pre-commercial biotech.
1b. Where does Taysha play?

Taysha plays in rare, genetically defined neurologic diseases, especially those affecting the CNS and those where small patient populations can support orphan-drug economics. Its strategic “where to play” is deliberately narrow: severe disorders with high unmet need, specialist prescribers, limited direct competition, and biology that may be suited to AAV gene delivery. More specifically, Taysha has concentrated on dosage-sensitive neurodevelopmental disease, with Rett syndrome as its clearest beachhead.
1c. How does Taysha plan to win?

Taysha’s plan to win rests on technical differentiation, focus, and rare-disease execution. The technical differentiation is especially important in Rett syndrome, where too little MECP2 expression causes disease but too much can also be harmful. Taysha has highlighted regulated-expression design as a core feature of TSHA-102. The second pillar is capital discipline: rather than spread resources across many early programs, Taysha has increasingly concentrated on the lead asset with the best chance of creating value. The third pillar is operating model design: use outside partners where sensible, preserve strategic flexibility, and potentially leverage larger partners for scale beyond what a small biotech can do alone.
1d. What capabilities must Taysha have in place?

To execute this strategy, Taysha needs strong capabilities in AAV vector engineering, translational neuroscience, clinical development in rare pediatric and neurodevelopmental disease, regulatory strategy, and chemistry, manufacturing, and controls (CMC). It also needs capabilities that are easy to underestimate in orphan disease: patient identification, site activation at specialist centers, advocacy-group engagement, long-term safety monitoring, and reimbursement planning for a one-time therapy. Because Taysha is small, vendor management and partner orchestration are themselves strategic capabilities, not just procurement tasks.
1e. What management systems does Taysha require?

Taysha needs management systems built around portfolio triage, cash control, quality, and cross-functional decision-making. That includes stage-gated investment decisions by program, tight safety governance, manufacturing quality systems suitable for biologics and gene therapy, and operating dashboards for enrollment, data-readout timing, and cash runway. For a company like Taysha, the management system is not separate from the strategy: if it does not enforce prioritization and execution discipline, the strategy can quickly become unaffordable.

2. What Are the Current Strategic Initiatives of Taysha?

Advance TSHA-102 in Rett syndrome. Taysha’s clearest current initiative is to move TSHA-102 through clinical development in Rett syndrome across relevant patient groups. That means generating additional safety and efficacy evidence, refining dose strategy, and building the data package needed for later-stage regulatory discussions.
Define a realistic registrational pathway. In rare disease, the science matters, but the approval pathway matters just as much. Taysha has been working to translate early clinical evidence into a development plan that regulators could support. That includes endpoint strategy, durability of response, patient-selection logic, and long-term follow-up design.
Build manufacturing and CMC readiness. For gene therapy, a promising clinical asset is not enough. Taysha must also show that it can consistently manufacture clinical and eventual commercial supply, validate analytical methods, manage comparability across manufacturing changes, and maintain quality and release standards.
Keep the portfolio focused. Publicly, the company has moved away from trying to advance a very broad set of CNS programs at once. The strategic initiative here is organizational as much as scientific: reduce distraction, preserve cash, and avoid spreading a small-company balance sheet across too many assets.
Use strategic partnerships to add capacity and validation. Taysha’s publicly disclosed relationship with Astellas matters because it potentially adds both capital and external validation. For a company at Taysha’s scale, a strong partner can improve development flexibility, geographic reach, and commercialization options.
Extend platform relevance beyond a single asset. While TSHA-102 is the lead priority, Taysha’s broader strategic ambition is to show that its regulated-expression approach has value in other dosage-sensitive CNS disorders. If successful, that would move the company from being viewed as a one-program story to being viewed as a platform with repeatable technical insight.

3. What Is the Business Model of Taysha?

Taysha is a pre-commercial biotech, so its business model has two layers: the current development-stage model and the future commercial model it is trying to build toward.

What customers actually buy. As of FY2024, no end-market customer buys a marketed Taysha medicine because the company has no approved products. Today, what the market effectively values are Taysha’s clinical assets, intellectual property, data, and commercial rights that can be partnered or licensed. In a future commercial state, hospitals and health systems would buy access to a one-time gene therapy administered through specialist centers.
Recurring versus one-time revenue. The long-run revenue model is mostly one-time treatment revenue, not recurring subscription-style revenue. A gene therapy for a rare monogenic disease is usually administered once, which means commercial performance depends on launch execution, patient finding, geographic expansion, and potentially follow-on indications rather than repeat use. That makes the business less recurring than many biopharma models.
Pricing power. Rare-disease gene therapies can have meaningful pricing power because they target severe unmet need, small populations, and potentially durable benefit. But pricing power is not automatic. It depends on clinical evidence, safety, durability, treatment logistics, and payer confidence. In Rett syndrome, payer scrutiny would likely be high because the therapy could be expensive and the disease burden is lifelong.
Why the business mix matters. For Taysha, the mix between wholly owned development, partnered rights, and future self-commercialized versus partnered geographies matters a great deal. Self-commercialization can preserve economics in the United States but requires more capital. Partnering can reduce risk and broaden reach but shares upside.
What drives margin. If Taysha reaches commercialization, gross margin would depend on vector yield, batch success rates, raw-material cost, fill-finish economics, royalties, and scale. Operating margin would depend heavily on how much the company spends on R&D beyond the lead asset and how lean it can keep commercial infrastructure in a specialist orphan market.
What drives cash generation. In the near and medium term, cash generation is negative and financing-dependent. Cash burn is driven by clinical trials, CMC work, regulatory activities, and general corporate overhead. Value creation before approval comes from de-risking the science and keeping the financing burden manageable.

4. What Products and/or Services Does Taysha Sell?

Taysha does not yet sell an approved commercial product. Its “products” are investigational therapies and associated intellectual property.

TSHA-102 for Rett syndrome. TSHA-102 has been Taysha’s lead program and strategic center of gravity. It is an investigational AAV gene therapy for Rett syndrome, a severe neurodevelopmental disorder commonly associated with mutations in MECP2. The program’s strategic importance is far greater than any other asset because it has the clearest near-term potential to create clinical and corporate value.
Rare CNS gene-therapy pipeline assets. Taysha historically assembled a broader portfolio of AAV-based programs for monogenic CNS disease. Some of these legacy programs have remained part of the company’s scientific base, but recent strategy has emphasized portfolio focus rather than broad parallel development. In other words, the broader pipeline still matters intellectually, but less so financially than the lead Rett program.
Licensing and partnering rights. For a company at this stage, commercial rights themselves are part of the offering. Taysha can create value by licensing territory rights, codevelopment rights, or platform know-how to larger companies that have more capital or commercial infrastructure.

5. What Are the Key Competitors or Peers of Taysha?

Taysha’s competitive set is mixed. A few companies are direct scientific competitors in Rett syndrome, while others are better understood as rare-disease gene-therapy peers or commercial benchmarks.

Neurogene. One of the closest direct peers in Rett-related gene therapy. Neurogene’s work in MECP2-related disease makes it especially relevant because both companies are trying to solve the same core gene-dosage challenge.
Acadia Pharmaceuticals. Acadia is not a gene-therapy competitor on mechanism, but it is commercially relevant in Rett syndrome because it markets DAYBUE, a symptomatic therapy. That gives Acadia presence with physicians, caregivers, and payers in the same disease area.
Passage Bio. A CNS-focused gene-therapy peer. Passage Bio is more comparable on operating model, manufacturing challenges, and investor framing than on exact indication overlap.
Voyager Therapeutics. A CNS gene-therapy and vector-engineering company whose relevance lies in technical approach, partnering strategy, and neurology orientation.
REGENXBIO. AAV gene-therapy company with vector know-how, manufacturing experience, and a history of partnering. More of a technology and business-model comparable than a direct Rett competitor.
Sarepta Therapeutics. A much larger rare-disease gene-therapy company. Sarepta is an indirect peer and execution benchmark, particularly in manufacturing, regulatory interaction, and commercialization of high-cost genetic medicines.
Ultragenyx Pharmaceutical. A rare-disease biotech with commercial infrastructure and gene-therapy activity. Ultragenyx is useful as a benchmark for orphan-launch execution and payer engagement.
PTC Therapeutics. A rare neurologic disease company with gene-therapy experience. PTC is relevant as a comparator for how specialized genetic medicines are developed and commercialized in small patient populations.

The important point is that Taysha does not compete only on molecule-versus-molecule science. It also competes for manufacturing capacity, clinical investigators, patient identification, investor capital, and partner attention.

6. What Is the Marketing Strategy of Taysha?

As a pre-commercial biotech, Taysha does not yet have a conventional product-marketing engine. Its current “marketing” is better described as scientific communication and ecosystem building. That includes engaging key opinion leaders, educating the Rett and broader rare-disease community, supporting disease awareness, participating in medical congresses, and communicating data clearly to regulators, investigators, partners, and investors.

If TSHA-102 reaches commercialization, Taysha’s likely marketing model would be a highly targeted rare-disease approach rather than mass promotion. The most important levers would be specialist physician education, treatment-center readiness, caregiver outreach through advocacy ecosystems, and payer evidence. In this model, brand advertising is secondary; trust, evidence, and treatment logistics matter more.

So marketing is currently a supporting capability, not the main differentiator. Taysha’s real differentiators are its science, clinical execution, and the credibility of its regulatory and manufacturing plan.

7. What Are the Key Customer Segments of Taysha?

Because Taysha is pre-commercial, it is more accurate to talk about stakeholder and future-customer segments than current product customers.

Patients and caregivers in Rett syndrome. These are the ultimate beneficiaries of the lead program. In rare disease, caregiver engagement and advocacy-group relationships are unusually important because they affect trial recruitment, community trust, and eventual treatment adoption.
Specialist physicians and treatment centers. Pediatric neurologists, geneticists, academic medical centers, and centers of excellence are the most important clinical customers in a future commercial model. They diagnose, refer, administer therapy, and generate post-treatment evidence.
Payers and health systems. Commercial insurers, Medicaid programs, and ex-U.S. national health systems are the economic gatekeepers for any approved gene therapy. In orphan disease, payer strategy can be almost as important as physician adoption.
Strategic partners. Larger pharmaceutical companies and regional partners are a real customer segment for a company like Taysha because they may buy development rights, commercialization rights, or codevelopment access.
Investors and capital providers. They are not customers in the normal commercial sense, but for a development-stage biotech they are essential counterparties. Their willingness to fund the company directly affects the speed and scope of execution.

Taysha is not diversified across many end markets. Its economic concentration is high, and much of its strategic value is tied to a small number of rare neurogenetic opportunities, especially Rett syndrome.

8. What Is the Sales Model of Taysha?

As of FY2024, Taysha had no commercial sales force because it had no approved products. The current go-to-market model is therefore clinical and partnership-driven, not revenue-driven.

If TSHA-102 reaches the market, the likely sales model would be a focused specialty model built around a small number of high-value accounts rather than a large field force. That would likely involve:

Direct engagement with specialist neurologists and genetic-disease centers in the United States.
Close coordination with medical affairs, patient-services, and reimbursement teams.
Limited-distribution logistics suitable for a high-cost, one-time biologic.
Potential use of partners outside the United States where a small company may not want to build its own infrastructure.

The channel structure matters because gene therapy is sold through relationships and operational execution, not shelf presence. A concentrated center-of-excellence model can support pricing and customer intimacy, but it also means growth depends on identifying nearly every eligible patient and making each treatment site operationally ready.

9. In What Geographies Does Taysha Operate?

Taysha’s corporate base is in Dallas, Texas, and its practical operating footprint is still centered in the United States. Unlike a commercial pharmaceutical company with large country organizations, Taysha’s geography is defined mainly by where it conducts research, manages vendors, runs clinical studies, and interacts with regulators.

Its clinical and development activities can extend beyond the United States through study sites, manufacturing partners, testing laboratories, and other outsourced providers. In that sense, Taysha already operates across borders, but not yet through a broad commercial network. The company appears geographically concentrated rather than fully diversified, which is typical for a small rare-disease biotech. Over time, if its lead program succeeds, the most logical commercial geographies would be the United States and other orphan-drug-friendly markets where specialist-center launches are feasible.

10. Who Are the Owners of Taysha?

Taysha is a publicly traded company on Nasdaq. As of its latest public filings, it did not disclose a controlling shareholder with majority ownership. Its shareholder base is primarily composed of institutional investors and public shareholders, with a strategic ownership element added by Astellas through a publicly disclosed 2023 transaction. For Taysha, that strategic shareholding matters less because of control and more because it can align capital with partnership optionality.

11. How Is Taysha Organized?

From a reporting standpoint, Taysha has operated as a single segment, which is common for a clinical-stage biotech. In practical terms, the organization is built around a lead program and a small number of enabling functions rather than around large commercial business units.

The core functions typically include research and translational science, clinical development, regulatory affairs, quality, CMC and technical operations, medical affairs planning, business development, and general corporate functions such as finance and legal. Because the company is relatively small, many activities that a large pharmaceutical company would perform internally are coordinated across external partners. That makes cross-functional program management especially important.

12. How Does Taysha Operate?

Taysha’s day-to-day operations revolve around advancing gene-therapy candidates from concept to clinic while preserving enough capital to reach key milestones. The operating model is typical of a specialized biotech but with the extra complexity that gene therapy adds in manufacturing, quality, and long-term safety follow-up.

Source and maintain intellectual property. Taysha’s origins are tied to licensed academic science, so IP management, licensing compliance, and know-how transfer are foundational operating tasks.
Design and refine vectors. The company works on transgene design, regulatory elements, and preclinical validation to improve the chance that a therapy is both effective and safe.
Manufacture clinical supply through specialized partners. AAV production, purification, analytical testing, and fill-finish are major operational workstreams with long lead times and high quality demands.
Run highly specialized clinical trials. Rare neurologic disease trials require expert investigators, small patient populations, careful protocol design, and deep engagement with families and advocacy communities.
Manage regulatory and safety obligations. Gene therapies require substantial documentation, product characterization, and post-dosing safety monitoring, often over extended periods.
Raise capital and manage partnerships. For a pre-commercial biotech, financing and partnering are part of operations, not side activities. They determine how much science the company can afford to pursue.

The main bottlenecks are usually manufacturing consistency, patient recruitment in very small populations, regulatory evidence standards, and the need to coordinate many external parties without losing speed or quality.

13. What Are the Growth Opportunities for Taysha?

Successful development and launch of TSHA-102. This is by far the largest opportunity. If Taysha can show convincing clinical benefit and build a workable approval pathway, the company could transition from development-stage biotech to commercial rare-disease company.
Expansion across patient cohorts and geographies. In rare disease, growth can come from broadening access across age groups, treatment settings, and geographies rather than from mass-market penetration.
Platform expansion into other dosage-sensitive disorders. If Taysha’s regulated-expression approach proves clinically meaningful, it could be relevant beyond Rett syndrome. That would be strategically important because it would reduce single-asset dependence.
Partnership-based growth. Taysha can create value not only by selling a product itself, but also by licensing rights, sharing development costs, and using partners to enter ex-U.S. markets or adjacent indications.
Reputation and financing leverage from clinical success. In biotech, strong early data can unlock better financing terms, stronger partnerships, and greater strategic flexibility. That is an indirect but important growth pathway.

The main constraints are equally clear: clinical and safety uncertainty, gene-therapy manufacturing complexity, competition in Rett syndrome and related rare-neurology markets, limited patient pools, and the constant need to balance scientific ambition against capital availability.

14. What Is the History of Taysha?

Taysha was founded in 2020 to commercialize AAV gene-therapy programs originating from The University of Texas Southwestern Medical Center. The company’s founding story is tied to academic neuroscience and gene-therapy research, including work associated with UT Southwestern researchers such as Dr. Steven Gray and Dr. Berge Minassian, alongside an industry management team built to translate that science into a public biotech company.

2020: Taysha was formed and quickly positioned itself as a CNS gene-therapy platform company. It also completed an initial public offering in 2020, giving it access to public-market capital unusually early in its life.
2020 to 2021: The company assembled a broad portfolio of rare CNS programs, consistent with the market’s then-strong appetite for platform biotech stories and gene-therapy expansion.
2022: As biotech funding conditions became more difficult, Taysha, like many peers, shifted toward portfolio prioritization and tighter spending. This period was strategically important because it marked a move from breadth toward focus.
2023: Taysha announced a strategic transaction with Astellas, bringing in capital and partnership validation. This reinforced the company’s emphasis on the most differentiated programs.
2024: The company continued to advance TSHA-102 and increasingly came to be viewed less as a multi-asset platform story and more as a focused Rett syndrome and CNS gene-therapy developer.

15. What Are the Key Suppliers to Taysha?

Suppliers matter a great deal to Taysha because gene therapy is operationally dependent on a relatively narrow set of qualified external partners. Public filings do not generally provide a long named list of suppliers, but the important supplier categories are clear.

Contract development and manufacturing organizations (CDMOs). These partners support plasmid production, viral vector manufacturing, purification, and process development.
Analytical testing and quality vendors. Release testing, potency assays, stability work, and comparability assessments are essential in gene therapy.
Fill-finish and cold-chain logistics providers. These suppliers handle sterile finishing, packaging, and temperature-controlled distribution to clinical sites.
Clinical research organizations and specialist sites. These are not “suppliers” in the manufacturing sense, but they are mission-critical operating partners that support site management, data collection, and trial execution.
Academic licensors and research collaborators. Taysha’s intellectual-property base is rooted in academic science, so licensors are strategically important inputs to the business model.

Supplier structure matters because switching costs can be high, capacity can be constrained, and any quality issue can delay both trials and regulatory progress.

16. How Does the Supply Chain of Taysha Function?

Taysha’s supply chain is less about mass-volume distribution and more about precision biologics manufacturing and controlled delivery.

Upstream sourcing. The process starts with plasmids, raw materials, reagents, and other specialized biologics inputs.
Vector manufacturing. AAV vector production is then carried out through specialized facilities with strict process controls.
Purification and analytical release. Each lot must pass stringent quality and potency tests before it can be used clinically.
Fill-finish and storage. Product is finished into its final presentation and maintained under controlled conditions.
Distribution to trial or treatment sites. Shipment is managed through a cold-chain process that prioritizes product integrity and scheduling precision.
Administration and follow-up. Delivery does not end at shipment; the operational chain extends into site readiness, dosing logistics, and post-treatment monitoring.

For Taysha, supply-chain reliability is strategic because patient populations are small, treatment events are consequential, and a failed batch or delayed shipment can have outsized clinical and financial effects.

17. What Is the Technology Strategy of Taysha?

Taysha’s technology strategy centers on using AAV gene delivery for monogenic CNS disease while differentiating through transgene control rather than through scale alone. In Rett syndrome, that matters because the core challenge is not only delivering MECP2, but delivering it in a way that avoids harmful overexpression. Taysha has emphasized its microRNA-responsive Auto-Regulatory Element, often referred to as miRARE, as a way to regulate expression levels more precisely.

This is an important strategic choice. Many small biotechs cannot outspend larger peers on manufacturing or commercial infrastructure, so they need a technical angle that changes the risk-reward equation. Taysha’s technology strategy appears to be exactly that: focus on a hard biological problem where improved control of gene expression could make the therapy more clinically usable. Technology here is both part of the product and an internal enabler of portfolio expansion into other dosage-sensitive neurologic disorders.

18. What Is the R&D Strategy of Taysha?

R&D is central to Taysha’s identity. The company’s strategy is not to outnumber competitors with dozens of programs, but to place focused bets where gene therapy may be biologically compelling and where technical differentiation can matter. In recent years, that has meant concentrating R&D resources on the lead Rett syndrome program and de-emphasizing a broader portfolio approach.

The main features of Taysha’s R&D strategy appear to be:

Target genetically validated disease. Taysha focuses on monogenic disorders where the biological target is comparatively well defined.
Work in severe unmet need. The company prioritizes diseases where current treatment options are limited and the medical need is obvious to regulators, clinicians, and caregivers.
Use translational design as a differentiator. The innovation is not only in selecting the gene, but in controlling expression and improving the risk profile of replacement therapy.
Advance with capital discipline. R&D choices are filtered through affordability. That may sound financial, but for small biotech it is an essential part of research strategy.
Generate data that can support partnering as well as approval. Strong R&D output improves both regulatory options and strategic optionality.

19. What Is the Finance Strategy of Taysha?

Taysha’s finance strategy is typical of a clinical-stage biotech but especially important because of the cost and complexity of gene therapy. The company’s financial objective is not near-term profitability; it is to maintain enough liquidity to advance the lead program through major value-inflecting milestones without excessive dilution or strategic drift.

Preserve cash runway. Public actions over the last several years have pointed toward tighter spending and sharper portfolio prioritization.
Allocate capital to the lead asset. For Taysha, TSHA-102 has been the primary destination for marginal dollars because it offers the most plausible path to near-term value creation.
Use partnerships to supplement balance-sheet capacity. Strategic transactions can provide cash, validation, and operating leverage without requiring Taysha to build everything itself.
Fund CMC and clinical milestones before broad expansion. In gene therapy, manufacturing readiness can consume large amounts of capital. Finance and operations therefore need to be tightly linked.
No shareholder payout orientation. As a development-stage biotech, Taysha’s capital-allocation priorities are reinvestment and liquidity, not dividends or share repurchases.

The broader point is that finance strategy is inseparable from corporate strategy here. A company with Taysha’s profile can create enormous value if it reaches the right milestone, but it can also destroy value by trying to do too much at once.

20. How Companies Like Taysha Leverage Independent Consultants through Umbrex

Umbrex has grown a global community of over 8,000 independent management consultants who are based in more than 50 countries. These consultants are alums of McKinsey, Bain, BCG, and other top consulting firms. Companies like Taysha engage Umbrex when they need talent with the training these top global firms provide but they do not need a full team with all the overhead. Umbrex has consultants across all functional areas including Strategy, Operations, Organization, Marketing, Sales, Finance, Technology, ERP, and AI. For a focused biotech like Taysha, that model is especially useful when management needs high-caliber project support around a few critical decisions rather than a long, expensive consulting engagement.

Rett syndrome launch strategy. Build a fact-based U.S. launch blueprint for TSHA-102, including treatment-center prioritization, patient-flow assumptions, and launch sequencing.
Rare-disease patient identification strategy. Map diagnostic pathways, referral bottlenecks, and center-of-excellence coverage to improve readiness for a concentrated orphan launch.
Gene-therapy market access and pricing strategy. Develop payer value story, evidence requirements, reimbursement scenarios, and contracting options for a one-time therapy.
Portfolio prioritization and capital allocation. Create a structured framework for deciding how much capital to put behind TSHA-102 versus platform, follow-on, or partnered opportunities.
CMC network and CDMO strategy. Assess manufacturing footprint options, vendor concentration risk, tech-transfer priorities, and scale-up economics.
Clinical-operations performance improvement. Design dashboards and operating routines to improve site activation, enrollment, data cleaning, and cross-functional trial governance.
Strategic partnering support. Prepare business cases, partnering materials, and valuation logic for ex-U.S. rights, co-development structures, or broader platform collaborations.
Medical affairs and advocacy engagement model. Define how to engage key opinion leaders, academic centers, and patient communities in a way that supports trust and future adoption.
Finance and runway scenario planning. Build board-ready scenarios around financing timing, milestone-based spending, and strategic alternatives under different clinical outcomes.
Cross-functional launch readiness PMO. Stand up a lightweight program management office to coordinate regulatory, supply chain, market access, medical affairs, and commercialization workstreams.